A Conversation With Mark McClellan, MD, PhD Mark McClellan, MD, PhD As evidenced at this year’s ASCO20 Virtual Scientific Program, oncology science, technology, and clinical practice are evolving at a rapid pace, bringing new challenges to the efficient and ethical practice of cancer care at all levels. To shed light on…
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies…
In a prospective cohort study, among patients hospitalized due to COVID-19 infection, those receiving cancer treatment had a higher rate of in-hospital mortality vs those…
Recently, the FDA approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative detection of cancerous tissue within the resection cavity…
Researchers have investigated whether spatial tissue analysis may help predict early posttreatment relapse and illuminate new potential therapies in patients with high-grade serous ovarian carcinoma.…
Researchers may have uncovered how the long-term daily use of aspirin may help prevent the development and progression of colorectal cancer, according to a recent…
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies…
The FDA approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)—includi…
On April 23, the FDA granted accelerated approval to the type II RAF inhibitor tovorafenib (Ojemda) for patients 6 months of age and older with…
Wendy Vogel, MSN, FNP, AOCNP, FAPO, of the Advanced Practitioner Society for Hematology and Oncology, summarizes a panel discussion in which she took part, on…
In a phase II study reported in the Journal of Clinical Oncology, Barker et al found that induction treatment with vismodegib followed by concurrent treatment…
